Jeffrey A. Bubis

Statistics

Publications

Citations

539

H-Index

Active since

2009

Affiliations

Florida Cancer Specialists & Research Institute(Current)

Texas Oncology

Memorial Sloan Kettering Cancer Center

University of Southern California

Heartland Regional Medical Center

Jeffrey A. Bubis is an author at Florida Cancer Specialists & Research Institute specializing in medicine, bone marrow failure syndromes, and clinical hematology.

Publications per year

2009–2017

Publications

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

Joachim von Pawel, Robert M. Jotte, David R. Spigel et al. · Journal of Clinical Oncology · 2014 · 344 citations · Full text

Medicine, Oncology, Pharmacology +13

A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure

Azra Raza, Farhad Ravandi, Anjay Rastogi et al. · Cytometry Part B Clinical Cytometry · 2013 · 64 citations · Full text

Medicine, Hematology, Pathology +14

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

Robert M. Jotte, Joachim von Pawel, David R. Spigel et al. · Journal of Clinical Oncology · 2011 · 49 citations

Medicine, Oncology, Pharmacology +12

A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure

Azra Raza, Farhad Ravandi, Anjay Rastogi et al. · Cytometry Part B Clinical Cytometry · 2013 · 38 citations

Medicine, Hematology, Pathology +14

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

Denise A. Yardley, Edward Arrowsmith, Brooke Daniel et al. · Breast Cancer Research and Treatment · 2017 · 27 citations

Medicine, Oncology, Pharmacology +14

1–5 of 6